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Abstract: 29 
The poor aqueous solubility of drugs has emerged as a major issue for pharmaceutical scientists 30 
from many decades. The current study explores the manufacture and development of a 31 
thermodynamically stabilized solid crystal suspension (SCS) of poorly water soluble drug 32 
efavirenz via hot melt extrusion. Efavirenz is a non-nucleoside reverse transcriptase inhibitor 33 
and belongs to BCS class II. The SCS was prepared using pearlitol and xylitol as a crystalline 34 
carrier. The drug-excipient blend was processed by hot melt extrusion with up to 50% (w/w) 35 
drug loading. Physico-chemical characterization of the SCS conducted via a scanning electron 36 
microscopy showed crystalline morphology.  The solid state analysis undertaken by using 37 
differential scanning calorimetry and hot stage microscopy confirmed that SCS are in 38 
crystalline state. Similarly, X-ray powder diffraction analysis revealed that pure drug, 39 
crystalline carriers and developed SCS are in crystalline state. The FTIR chemical imaging 40 
analysis of SCS formulations showed a homogeneous drug distribution within respective 41 
crystalline carriers while an advanced chemical analysis via atomic force microscopy and 42 
Raman analysis complemented the foregoing findings of the FTIR imaging. The developed 43 
SCS1 formulation showed up to 81 fold increase in the solubility and 4.1 fold increase in the 44 
dissolution rate of the drug compared to that of the bulk substance. Surprisingly, the developed 45 
SCS formulation remained stable for a period of more than one year at accelerated conditions 46 
inferred from dissolution studies. It can be concluded that the SCS approach can be used as an 47 
alternative contemporary technique to enhance the dissolution rates of many other poorly 48 
water-soluble drugs by means of thermal HME processing.  49 
 50 
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 52 
1. Introduction 53 
In the recent years, hot-melt extrusion (HME) has been evolved as a promising 54 
pharmaceutical manufacturing technology for a wide variety of pharmaceutical applications 55 
such as taste masking of API (Maniruzzaman et al., 2014;), sustained oral drug delivery (Claeys 56 
et al., 2015;), cocrystal drug delivery (Moradiya et al., 2014). More recently HME has 57 
successgfully been used as a continuous manufacturing technique by implementing the Quality 58 
by design (QbD) and process analytical technology (PAT) paradigm (ref). Different types of 59 
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dies may be employed to obtain desired shape of extrudes via HME. Using these different types 60 
of dies formulation products such as oral fast dissolving films, transmucosal, transdermal DDs 61 
( Park et al., 2015), intravaginal DDs (Clark et al., 2012), implants (Stanković et al., 2013), 62 
stents and ophthalmic inserts (Lee et al., 2010) have been manufactured and reported in 63 
literature. There are several commercial products available in market to date primarily made 64 
by HME and these include Ritonavir - Norvir® (Sherman and Steinberg, 2011), Ibuprofen - 65 
Nurofen® (Gryczke et al., 2011), Lopinavir/Ritonavir - Kaletra® (Klein et al., 2007), Metformin 66 
HCL/Vildagliptin - Eucreas® (Stanković et al., 2015) and Greisofulvin Gris-PEG® (Stanković 67 
et al., 2015) etc.. The HME has successfully be optimized and exploited in solubilization of 68 
poorly soluble drugs in crystal engineering and by formation of pharmaceutical cocrystals 69 
(Dhumal et al., 2010; Moradiya et al., 2014)  70 
Recently, a new phrase called solid crystal suspensions (SCS) was proposed, which is 71 
an intimate mixture of a crystalline drug with crystalline carrier resulting in the formation of a 72 
stable formulation with significantly faster dissolution rate, comparative to pure drug using 73 
HME (Reitz et al., 2013; Thommes et al., 2011). In SCS, the crystalline drug is suspended in 74 
crystalline carrier matrix without facilitating any interactions between the drug and the 75 
crystalline matrices  but producing a thermodynamically stable system. Unlike the starting 76 
components, the newly formed crystallinelattice also completely differs from the traditional 77 
solid dispersions (Chiou and Riegelman, 1971; Marsac et al., 2006). The physical stability of 78 
SCS is very high because of no existence of amorphous phase in the system , compared to other 79 
types of traditional solid dispersions (Thommes et al., 2011; Urbanetz, 2006). The increase in 80 
dissolution rate by SCS approach is due to API particle size reduction within the highly soluble 81 
crystalline carrier and improvement in wettability and thus the solubility. 82 
EFV is used as a part of highly active antiretroviral therapy (HAART) in the treatment 83 
of human immunodeficiency virus (HIV) type 1 disease. It is a white, crystalline, non-84 
hygroscopic powder which is insoluble in water (Zakeri-Milani et al., 2009).  Hence, there is 85 
strong need to overcome the issue of poor solubility of EFV in order to enhance oral 86 
bioavailability.  It has been reported in literature that various polyols, superdisintegrants and 87 
polymers can be used as a carrier in HME for solubilization of poorly water-soluble drugs 88 
(Moradiya et al., 2015;).  89 
 90 
The aim of the study was to explore SCS concept for poorly water-soluble drug EFV 91 
using highly soluble crystalline carriers by HME technology. In this context, we report the 92 
formation of crystalline molecular dispersions of poorly water-soluble drug Efavirenz (EFV).. 93 
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In the present study, we also have explored polyols such as xylitol and mannitol as a crystalline 94 
carrier for SCS formation, due to their rapid crystallization behaviour (Cares-Pacheco et al., 95 
2014)as reported earlier (Thommes et al., 2011). The physico-chemical characterization of the 96 
SCS and the stability of the final optimized formulation was thoroughly accessed.  97 
 98 
 99 
2. Material and methods: 100 
2.1 Materials 101 
Efavirenz was obtained as a gift sample from Laurus labs, India. Mannitol (Pearlitol 50 C) was 102 
obtained from Rouquette, France and Xylitol from Signet chemicals, India. All the solvents 103 
used were of analytical grade obtained from Sigma Aldrich chemicals, India. 104 
 105 
2.2 Selection of polyols as carrier for HME: 106 
The solubility parameter difference (∆δ) between API and excipient gives possible idea on the 107 
miscibility of the drug delivery system (Van Krevelen and Te Nijenhuis, 2009). If the solubility 108 
parameter difference is less than 7 MPa1/2 difference is generally accepted as an indication of 109 
miscibility whereas for a difference of more than 10 MPa1/2 the system is likely to be 110 
immiscible (Greenhalgh et al., 1999; Dukeck et al., 2013). Efavirenz is poorly water-soluble 111 
drug (M.P. 138-140°C), which is highly hydrophobic. Hence, its solubility is sturdily hindered 112 
by high crystal lattice energy. Thus, we choose polyols such as xylitol and pearlitol as 113 
hydrophilic crystalline carriers for solubility enhancement of EFV. Solubility parameters 114 
usually used to access mixing capability between polymers and drugs as reported in literature 115 
(Fule et al., 2016; Lu et al., 2015). Based on the group contribution method calculation  116 
solubility parameters of EFV, pearlitol (mannitol) and xylitol are 24.55 MPa1/2 (Sathigari et al., 117 
2012), 40.5 MPa1/2 (Thommes et al., 2011), and 36.86 MPa1/2 (Kitak et al., 2015), respectively. 118 
Solubility parameter difference (∆δ) between EFV and carriers is between 11.5-15 MPa1/2. We 119 
have purposely chosen carriers that have a solubility difference within the limit for 120 
immiscibility in order to articulate the effect of the critical parameters like drug-polymer ratio, 121 
screw speed, extrusion temperature, residence time and stability of final dosage formulation. 122 
 123 
2.3 Preparation of EFV solid crystal suspensions by HME 124 
Hot melt extrusion was carried out using a Thermo Scientific HAAKETM MiniLab II 125 
Micro compounder (Thermo scientific, Newington, NH, USA) with co-rotating twin screws.  126 
Batches were taken in different ratio of EFV to carriers to optimize the final formulation. 127 
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Optimized batches were taken in the ratio of EFV to either xylitol or pearlitol by preparing 128 
physical mixture using mortar-pastle. HME was performed having drug to carriers in 20:80 129 
and 50:50 ratio of both the polyols as shown in table 2.  130 
Accurately 20 gm powder physical mixtures were prepared and extruded through the 1 131 
mm diameter die at optimized temperature with 100 rpm speed (Chen et al., 2006). For melt 132 
extrusion with pearlitol, the extrusion was carried out at temperature 138-140°C, (melting point 133 
of EFV), with the screw speed of 100 RPM. Both xylitol and pearlitol crystallizes after the melt 134 
extrusion process, the extrudates obtained were further cooled at room temperature and grinded 135 
to form powdered material and termed solid crystal suspension. SCS samples were kept in 136 
umber colored bottles for further physicochemical characterization.  137 
 138 
2.4 Thermogravimetric analysis (TGA) 139 
TGA studies were carried out using Mettler Toledo TGA/SDTA (Mettler Toledo, 140 
Switzerland) operating with Stare software version Solaris 2.5.1. Accurately weighed (3–5 mg) 141 
sample was loaded in alumina crucible and heated at the rate of 10 °C/min over a temperature 142 
range of 35–250 °C, under nitrogen purge (50 mL/min), to determine loss in weight. 143 
 144 
2.5 Saturation solubility study 145 
The EFV and SCS were analysed for saturation solubility study in 0.1N HCl containing 146 
0.2% sodium lauryl sulfate (SLS) maintained at 37 ± 0.5 °C. Excess amounts of API and SCS 147 
were added to 10 ml of dissolution media and capped glass test tubes were kept in a shaking 148 
incubator (Boekel scientific, USA) maintained at 37±0.5°C with75 rpm speed for 48 hrs. The 149 
solutions in the test tubes were vortexed and kept for centrifugation at 5000 rpm for 10 min. 150 
The supernatant layer was then filtered through 0.45µm millipore membrane filter and 151 
analyzed for drug content by HPLC. The study was carried out in triplicate. 152 
 153 
2.6 In vitro dissolution studies 154 
The In vitro dissolution studies were conducted using a USP type II dissolution 155 
apparatus. From SCS amount equivalent to 100 mg of EFV was ﬁlled into capsules and the 156 
capsules were then placed in sinker and put into dissolution medium within the apparatus. The 157 
dissolution studies were performed under sink conditions and the medium was 1000 mL of 158 
0.1N HCl containing 0.2% sodium lauryl sulfate (SLS) maintained at 37 ± 0.5 °C with speed  159 
50 rpm. At various time points like 15, 30, 45, 60 and 90min, the samples were withdrawn and 160 
an equal amount of fresh medium was added to the ongoing dissolution medium vessel. These 161 
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samples were analysed using UV-spectrophotometer at 248 nm. The dissolution studies were 162 
performed in triplicate. 163 
 164 
2.7 Differential Scanning Calorimetry (DSC) 165 
DSC analysis was performed to check the physical state of SCS with respect to pure 166 
EFV, SCS, xylitol and pearlitol  using Pyris-6 DSC Perkin Elmer (Lee et al.).  Approximately 167 
3-4 mg of sample was hermetically sealed in aluminum pan.  An empty aluminum pan was 168 
used as a blank. Samples  were  heated  at  the  rate  of  10°C/min-1 from  30°C - 300°C  under 169 
an inert atmosphere was maintained purging nitrogen gas at a flow rate of 18 ml/min. The Pyris 170 
manager® software was used for post experimental analysis.  171 
  172 
2.8 Hot stage microscopy (HSM) 173 
HSM was carried out to observe thermal transitions in the SCS formulations. Leica 174 
160DMLP polarized microscope (Leica Microsystems Wetzlar GmbH, Wetzlar, Germany) 175 
equipped with Linkam LTS hot stage was used for this study. SCS samples was mounted in oil 176 
on glass slide and heated from ambient temperature to 200 °C, at a heating rate of 10 °C/min. 177 
Changes in morphology behaviour in all samples were collected as a video recording using 178 
JVS color video camera and analyzed using Linksys32 software. This is potential technique to 179 
understand the morphological behavior of extruded material. 180 
 181 
2.9 X-ray diffraction (XRD) analysis 182 
XRD was used to determine the physical state drug in SCS as compared to pure carrier 183 
materials. X-ray diffraction using an X-ray diffractometer (Bruker D8 Advance, WI, USA) 184 
with a scan speed of 2°/min over a range of 2–50 (2Ɵ) was used. The samples were placed in 185 
a zero background sample holder and incorporated on a spinner stage.  186 
 187 
2.10 Structural analysis by FTIR 188 
 FTIR spectra of the EFV and SCS were recorded using a Fourier transform infrared 189 
spectrophotometer model 4100 (Spectrum GX-FT-IR, Perkin Elmer, USA) to investigate any 190 
possible interactions between the drug and carriers.    The    samples    were  premixed with 191 
KBr using mortar and pestle and KBr disks were prepared using hydraulic press. The scanning 192 
range was set at 4000 to 400 cm-1 with resolution of 4 cm-1 193 
 194 
2.12 FTIR spectroscopic Imaging 195 
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The optimized SCS formulation was characterized for FTIR imaging. Vertex 80/ 196 
Hyperion 3000, Bruker, Germany) instruments with liquid nitrogen cooled single mercury-197 
cadmium-telluride (MCT) focal plane array detector 128 × 128, (Santa Barbara Focal plane, 198 
Goleta, California) at range: 4000-900 cm−1 was used for the analysis(Verma et al., 2012). Then 199 
The powder sample was placed on temperature-controlled stage. Position of the accessories 200 
were adjusted such that a good focused image was obtained. The spectrometer was setup in 201 
attenuated total reflectance (ATR) mode using a diamond internal reflection element (IRE). 202 
The images were acquired with a spectral resolution of FTIR 0.2 cm−1and 32 co-added scans 203 
by using OPUS® 6.5 software with an acquisition time of approximately 2 min.  204 
 205 
2.13 Raman spectra and mapping 206 
The Raman spectra of the SCS formulations were recorded with a LabRamHR800 207 
(Horiba Jovan Yvon, UK) equipped with a 633-nm Ar–Ne laser. The laser excitation light was 208 
transmitted through a notch filter towards confocal hole, and entrance slit of spectrograph. The 209 
stokes-shifted Raman scatter was dispersed using 1800 groove/min grating onto a peltier-210 
cooled changed-coupled device (CCD, Andor Technology PLC) to capture a spectrum. Each 211 
samples spectra measured using continuous readout of Raman shift spectrum from 2800 to 212 
3000 cm-1. In all experiments, a near-IR laser (785 nm) of 250 mW power was employed. 213 
Spectra were acquired using a 50 × objective and a 300 μm confocal hole. Raman spectras were 214 
collected using a SYNAPSE CCD detector (1024 pixels). For milled extrudate compact, maps 215 
were acquired over 8-10 min 2800 to 3000 cm-1 regions using a fixed grating to allow relatively 216 
rapid mapping. Raman mapping or imaging of SCS was carried out to understand the drug 217 
distribution pattern inside polymer matrix and check its uniformity (Widjaja et al., 2011).  218 
Analysis of data sets can be performed quickly and simply to provide information on peak 219 
parameters (e.g., position, width, area). LabSpec 6 software is used to run the analysis (Fule et 220 
al., 2016; Furuyama et al., 2008). 221 
 222 
2.14 Preparation of extrudates for AFM characterization 223 
Fractured fresh extrudate with smooth surfaces were used for microscopic 224 
investigations using AFM.  The freshly fractured extrudates were mounted on an optical glass 225 
slide by use of a 2 component epoxy resin, which hardened within ~6 min to get fracture surface 226 
as horizontal as possible, so that it shall facilitate to enable non-destructive imaging (Turner et 227 
al., 2007). JXA-8530F Hyper Probe Electron Probe Micro-analyzer instrument by JEOL was 228 
employed for AFM analyses. Freshly fractured extrudates on microscopic glass slides were 229 
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mounted on the micrometer positioning stage of a dimension icon AFM with accelerating 230 
voltage of 1-30kV. Probe current range was kept between 10 pA to 200 pA and images were 231 
obtained. An atomic force microscope (AFM) scans the surface of a specimen with a very sharp 232 
tip mounted to a cantilever, deflections of which are directly related to surface nanoscale 233 
topography and various other physical properties. Between 10 and 25 regions per sample were 234 
programmed to be automatically characterized using the software routine “programmed move” 235 
in tapping Mode. Height, phase, and amplitude images were collected simultaneously, using 236 
etched silicon cantilevers with a nominal spring constant of k=40–100 N/m (JEOL AFM 237 
Probes). Image areas of 10×10 mm were recorded at a resolution of 1024×1024 pixels. All data 238 
were batch-processed using Scanning Probe Image Processor (SPIP 5.1.1) (Fule et al., 2016; 239 
Lauer et al., 2013). 240 
 241 
2.15 Analytical method (HPLC) 242 
The assay of EFV SCS was assessed using high-performance liquid chromatography 243 
(HPLC) system of JASCO corporation equipped with auto sampler (AS-2055 plus, intelligent 244 
sampler), photodiode array detector (JASCO corp.). A Phenomenex Luna® reverse-phase C18 245 
column (150 x 4.6 mm; 5µm particles) was used as a stationary phase. The mobile phase was 246 
composed of a mixture of buffer (Ammonium acetate buffer, pH maintained at 7.5): acetonitrile 247 
in the ratio 40:60 (v/v). The buffer was prepared by dissolving ammonium acetate in 1000 mL 248 
of water; maintain the pH at 7.5 ± 0.05. The flow rate was 1.5 mL/min, with injection, volume 249 
was 20 µL and the detection of EFV was done at 248 nm with the retention time of 3.38 ± 250 
0.05min. Drug content uniformity was assessed by accurately weighing SCS equivalent to 10 251 
mg of EFV were dissolved in 10 mL of methanol and appropriately diluted. These samples 252 
further centrifuged (Centrifuge Eppendorf) for 5 min at 5000 rpm and drug content was 253 
quantified using previously delineated HPLC procedure.  254 
 255 
2.16 Stability studies 256 
 The impact of temperature and humidity conditions on chemical and physical stability 257 
of the EFV SCS was determined according to ICH guidelines. A portion of EFV SCS filled 258 
into capsules was stored in a HDPE bottles to at 40°C/75% relative humidity for 12 months. 259 
Differential scanning calorimetry and powder XRD studies were carried out to determine 260 
crystallinity of EFV SCS at 0, 6 and 12 months. The in vitro dissolution studies also carried 261 








3. Results and discussions: 268 
3.1 TGA analysis 269 
In case of HME processing, the study of thermal profiles of API and individual 270 
excipients employed in a formulation is considered a decisive step. The EFV and individual 271 
polyols used in the formulations were evaluated for thermal stability at elevated temperatures. 272 
TGA studies revealed that EFV, xylitol and pearlitol were stable under the employed extrusion 273 
conditions and exhibited less than 2% weight loss, when subjected to heat ramp (Fig.1). In this 274 
context, all formulations were processed below 150°C temperature, henceforth it was 275 
concluded that processing temperatures studied were suitable during the HME process.  276 
 277 
3.2 Saturation solubility study 278 
The solubility of SCS was found to be improved in both dissolution media distilled 279 
water (1) and 0.1N HCl (2) containing 0.2% SLS (DiNunzio et al.). The apparent solubility of 280 
pure EFV was found to be 9 ± 1.12 µg/ml and 0.212 ± 0.32 mg/mL in dissolution medium 1 281 
and 2, respectively. The solubility of SCS was substantially improved as shown in Fig 2.  The 282 
apparent solubility of SCS was maximum for  SCS1 formulation with about 161 µg/ml and 283 
1.67 mg/ml solubility in dissolution medium of 1 and 2, respectively. It is about 19 and 80 folds 284 
increase in the solubility compared to that ofof pure EFV. The solubility of SCS is improved 285 
due to the highly hydrophilic nature of pearlitol and xylitol in water. It has been reported in 286 
literature that polyols facilitates hydration of hydrophobic regions in drug molecules (Arakawa 287 
and Timasheff, 1982). The same kind of effect would result in to favored wetting of 288 
hydrophobic drug particles.  Xylitol and pearlitol acts as a better solvent carrier in HME process 289 
facilitating improved solubility by imparting wetting to drug particles (Thommes et al., 2011). 290 
The SCS formulation approach developed by HME process, results in the formation of 291 
a suspension of API in molten carrier system of polyols. The molten xylitol found somewhat 292 
better solvent for EFV due to its relatively lowermelting point (94-96 °C) and acts as a better 293 
carrier to make a molten mass with EFV resulting in formation of solid crystal suspensions. 294 
The improved solubility of EFV SCS results due to improved wettability and reduced particle 295 
size. The extrusion process results in to reduction in particle size of drug (Reitz et al., 2013).  296 
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Remarkably, SCS2 and SCS4 formulations reveals smaller particle size than that of 297 
with SCS1 and SCS3. The smaller particle size of SCS2 and SCS4 is ascribed to lower shear 298 
forces in 20% drug loaded formulations, which exhibits, having availability of higher 299 
proportion of molten xylitol and pearlitol in formulation mixture during hot melt extrusion 300 
processing (Thommes et al., 2011). In extrusion process, the intense mixing and agitation of 301 
formulation system results in uniform distribution of fine particles.   302 
 The improved solubility of solid crystal suspension formulations imparts due to 303 
physical configuration of hot melt extrudate than that of physical interaction between drug and 304 
polyols as crystalline carriers. The API particles become intimately mixed and entirely 305 
surrounded by highly hydrophilic carriers, resulting into improved wetting by aqueous 306 
dissolution medium due to increased surface area of drug particles leading to improved 307 
solubility of EFV SCS compared to pure EFV.  308 
   309 
3.3 In vitro dissolution rate study 310 
 The invitro dissolution studies were conducted  to assess the performance of SCS 311 
formulations compared to pure EFV. The Fig. 3 indicates dissolution profiles of pure EFV, 312 
SCS formulations and marketed capsule EFAVIR®. It has beenreported in literature that the 313 
bulk EFV has an aqueous solubility of 5.2 ± 0.3 µg/mL (Maurin et al., 2002). It can be seen 314 
that pure EFV showed slow dissolution rates of 22% at 45 min, 24% at 90 min. In contrast, all 315 
SCS formulations showed significant increase in dissolution rate of more than about 70% at 316 
the end of one hour. Optimized batch i.e. SCS1 (20% EFV) and SCS2 (50% EFV) formulated 317 
with xylitol showed the dissolution of 100% and 93%, respectively in 1hr, which is 318 
approximately 4.1 and 3.9 folds higher than that of pure EFV. In addition, the SCS3 (20% 319 
EVF) and SCS4 (50% EVF) made using pearlitol showed slightly slower dissolution of 88% 320 
and 82%, respectively after 1 hr. In all formulations, dissolution rate has been significantly 321 
improved compared to  that of pure EFV (P < 0.05). The corresponding physical mixture of 322 
EFV with xylitol and pearlitol showed little increase in dissolution rate. However, dissolution 323 
from physical mixture is not as effective as that from the developed SCS formulation. The 324 
marketed EFAVIR® capsule showed 98% drug release in 1 hr, which is similar to that of the 325 
optimized SCS formulation (P < 0.05 Fig.3).  326 
  It is expected that the solid crystal suspensions prepared of  crystalline materials will 327 
enhance the physical and chemical stability of the drug. Therefore, the stability studies 328 
conducted at accelerated condition for 6 months showed no significant change in the release of 329 
the crystalline poorly soluble EVF.The Fig.4 shows dissolution profiles of SCS1 and SCS3 330 
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formulations kept for accelerated stability conditions (40° C/ 75% RH) at day 1, 6 months and 331 
12 months. Differences in dissolution profiles between fresh and 12 month’s stored samples 332 
are statistically non-significant (P< 0.05). The formulations SCS3 and SCS4 produced using 333 
pearlitol can be considered physically stable. In contrast, SCS1 showed statically significant 334 
difference (P < 0.2) in dissolution profiles during the storage at the accelerated condition. The 335 
SCS prepared from xylitol showed physical and chemical instability and showed decrease in 336 
dissolution rate (Rowe et al., 2009). This could be attributed to the nature of the possible 337 
interaction between the drug and the crystalline excipients during the extrusion. 338 
 339 
3.4 Differential Scanning Calorimetry (DSC) 340 
 The thermal transitions of the bulk EFV, excipients and the extruded formulations were 341 
studied by DSC and are depicted  in Fig. 5. EFV (Fig. 5.a) was characterized by thermogram 342 
showing a single, sharp melting endothermic peak at 139.60°C indicating crystalline nature of 343 
drug. The xylitol (Fig 5b) showed a sharp endotherm at 92.8°C corresponding to its melting 344 
and confirming its crystalline nature. Pearlitol showed a sharp endotherm peak 164.8°C 345 
inferring to its crystalline nature. In case of all SCS formulations, two melting endotherms have 346 
been seen (Fig 5c, d, f,g). The melting endotherm of xylitol and pearlitol were found broadened 347 
with less intensity and were shifted to slightly lower temperature compared to the bulk 348 
substances in all SCS formulations. This was expected since the presence of a molten liquid of 349 
sugar alcohols often reduces, up to certain extent, than melting point of the higher melting 350 
component. There were no glass transitions observed for either the excipients or final SCS 351 
extrudates, probably due to the strong crystallization tendency of  both xylitol and pearlitol (Yu 352 
et al., 1998; Zhang et al., 2012).  353 
The SCS appeared to be a physical mixture of two components in different proportions 354 
for both polyols systems. In case of SCS granulate melting peaks were found broader for xylitol 355 
and pearlitol, this may be due to heat flux in respective sample and is artifact of DSC analysis 356 
(Reitz et al., 2013).  357 
 358 
3.5 Hot stage microscopy: 359 
 HSM studies were conducted to visually determine the thermal transitions and extent 360 
of melting of EFV, SCS1 and SCS3 extrudates prepared by HME. Fig. 6A (EFV), Fig. 6B 361 
(SCS1) and Fig. 6C (SCS3) infers the melting pattern at different stages such as notation 1 362 
infers initial melting, 2 – onset of melting and 3 – infers complete melting of the respective 363 
extrudate and pure EFV and SCS formulations at different points as shown in Table 3. 364 
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 The hot stage microscopy results are in good agreement with DSC results as the 365 
complete melting of respective substances was as same as DSC endotherm peaks. HSM 366 
technique has advantage as this microscopic method can be applied to more mixture systems 367 
compared to other analytical methods due to fewer assumptions involved (Yang et al., 2011).  368 
The marked temperature at left bottom corner of each screen indicates temperature of sample 369 
(A1-intinal melting, A2-onset of melting, A3-complete melting). The desolvation of respective 370 
materials was confirmed by various events in HSM analysis. EFV shows needle shaped 371 
crystals, which were transparent at room temperature. At respective onset of melting point 372 
showed crystals quite deformed and opaque in temperature range 135-145° C, confirming 373 
melting of EFVas indicated by DSC and TGA. 374 
 375 
3.6 X-ray diffraction spectroscopic analysis: 376 
 The XRD diffratcograms of EFV, xylitol, pearlitol and respective SCS are shown in 377 
Fig. 7. The PXRD diffractogram of EFV shows sharp multiple peaks, signifying the crystalline 378 
nature of drug. The xylitol, pearlitol also show sharp intensity peaks due ot its crystalline 379 
structure.,Similarly, all of theextruded formulations show characteristic intensity peaks due to 380 
the presence of the crystalline substances in the formulations. The XRD diffraction peaks of 381 
SCS granulate infer that the  obtained SCS formulation is a physical mixture of two compounds 382 
(Reitz et al., 2013).  383 
 During the extrusion process, pearlitol (i.e. mannitol) which is occurred in its β form, 384 
converted into more stable form of β– modification of mannitol instead of converting to its 385 
metastable α formas reported in previously by Thommes et. al (Thommes et al., 2011). This 386 
was attributed to the partial melting of the mannitol particles during the HME process. 387 
However, the existence of β –transformation seeds in the melt extrudates favors crystallization 388 
of the stable β –modification, which is kinetically stable and remains as such for indeﬁnite 389 
periods without spontaneous transformation (Reitz et al., 2013).  This indicates that both the 390 
drug and mannitol are present in crystalline form in ﬁnal extrudate as form β -mannitol.  391 
 In case of xylitol, all extruded formulations exhibited similar characteristic peaks due 392 
to the presence of the crystalline drug and the sugar (Fig. 8). Fast crystallization of the 393 
excipients having high melting points is a critical element for producing crystal suspensions. 394 
Xylitol having melting point of 96 - 97° C exhibited better carrier system than that of pearlitol 395 
with melting point of 165° C, where the drug was melted and adsorbed in the carrier system. 396 
The SCS3 and SCS4 showed sharp diffractogram peaks resembling the EFV, which was 397 
present in higher EFV loads. 398 
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  399 
3.7 FTIR analysis: 400 
The FTIR spectra’s of EFV, xylitol, pearlitol and SCS system are depicted in Fig. 9. 401 
The FTIR spectra of EFV Fig. (9a) showed characteristics peak of 3314 cm-1 (-NH stretch), 402 
1742 cm-1 (C=O stretch), 1492 cm-1 (C ≡ C benzene ring stretch), 1240 cm-1(-CN stretch), 1165 403 
cm-1 (CO stretch), 1096, 1057 and 1074 (C-O-C stretch) and 689 and 652 cm-1 (-CF stretch). 404 
Xylitol Fig. (9b) as well as pearlitol Fig. (10e)  showed characteristics broad peak at 3100 – 405 
3400 cm-1 resembling the maximum number of hydroxyl moieties (-OH stretch). In addition to 406 
that 1165 cm-1 (-CO stretch), 1050 – 1300 cm-1 confirms the carboxylic acid and alcohol groups 407 
moieties. The FTIR spectra’s of the developed SCS1 and SCS2 formulations are shown in Fig. 408 
(9c, d) and SCS3 and SCS4 formulationsin Fig. (10 f, g) which infers the combination of 409 
characteristics peak of EFV and respective polyols. These results resemblance that formation 410 
of SCS system by HME did not result in any molecular interaction between EFV and respective 411 
carriers (Thommes et al., 2011). The characteristics broad peak stretch at 3100 – 3400 cm-1 412 
(shown by dotted rectangle) was retainedin the SCS system inferring to maximum number of 413 
hydrophilic groups, which has been provided by hydrophilic carriers (Pawar et al., 2015). The 414 
wave stretch of 2243 cm-1 corresponding to the –CN stretch of EFV was distinctively seen in 415 
all SCS1, SCS2, SCS3 and SCS4 formulations (shown from top side by arrow). Henceforth the 416 
SCS formulations may result in diffusion into dissolution medium and accelerated release of 417 
the developed SCS formulations compared to pure EFV.  418 
 419 
3.8 FTIR chemical imaging analysis 420 
FTIR chemical imaging results of SCS3 has been shown in Fig. 11. The 3D image and 421 
IR reflectance spectrum of point of interest of SCS3 specifies the surface compositional 422 
homogeneity of EFV in pearlitol matrices. Use of FTIR imaging spectrum to understand 423 
distribution of API at microscale level been reported in literature previously (Alhijjaj et al., 424 
2015; Ewing et al., 2015; Feng et al., 2015; Vo et al., 2016). 425 
FTIR imaging was constructed based on ATR mode using a diamond internal reflection 426 
element (Irene et al.). To understand the homogeneity of EFV in SCS3 at microscale level, the 427 
extrudate was ground to powder pror to the imagingRandom spots on the extrudates were 428 
analysed by ATR. The wave number of 2243 cm-1 corresponding to the –CN stretch, uniquely 429 
distinguishes in EFV in the SCS3 (Fig. 11C) was used to generate the FTIR chemical images 430 
(Pawar et al., 2016a).  The peak range at 2186 cm-1 to 2289 cm-1 was selected as the chemical 431 
imaging reflectance spectrum for both analysis. Fig. 11A and B represents the 3D image and 432 
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C shows the reflectance spectrum (Vo et al., 2016). The 3D graph is illustrated by distribution 433 
of the EFV by red colors and pearlitol as carrier system by green-yellow color. From this FTIR 434 
chemical imaging analysis study, it can be concluded that EFV is distributed in carrier systems 435 
homogenously. The results obtained by FTIR imaging could be a versatile analytical technique 436 
for characterization of extruded components for the distribution of API in polymer system by 437 
HME process (Vo et al., 2016).  438 
 439 
3.9 Raman analysis 440 
The intensity of spectral features in any particular solution is dependent on the 441 
concentration of particular species. The Raman spectra of SCS1 and SCS3 has been shown in 442 
Fig. 12. Raman spectroscopy and its mapping technique are useful tools to study the crystalline 443 
and amorphous states (Saerens et al., 2011), including discrimination of crystalline drug in SCS 444 
as shown in Fig. 12. Raman spectra are generally robust to temperature changes. In addition, 445 
by describing the distribution of the drug and respective carrier, it could be predicted how drug 446 
crystals formed during preparation. It also identified distribution of crystalline form of the drug 447 
substance and respective carrier. The presence of drug in crystalline form with uniform 448 
distribution in SCS in the images of the hydrophilic regions in SCS described by the width at 449 
around 3027 to 3091 cm−1 green area was thought to be the carrier. (Mishra et al., 2012). Green 450 
fluorescence is due to polymer matrix and blue related to the drug particles. The distribution 451 
pattern has been illustrated and the optical image confirmed the presence of drug distributed 452 
inside polymer matrix. (Fule et al., 2016; Saerens et al., 2011).  453 
 454 
3.10 AFM analysis 455 
Molecular fracture roughness data as displayed in 3D surface image and surface 456 
roughness data calculated from at least 10 images on each sample, which gives morphological 457 
surface interactions in detail of both SCS1  and SCS3 samples as shown in Fig.13. It can be 458 
claimed from the AFM analysis that there is a high level of surface interaction between the 459 
drug inside respective sugar matrix observed in extrudates. AFM characterization have the 460 
potential to identify the uniform molecular disperse mixture. AFM has potential to quantify 461 
different phases and it can be determined through imaging at molecular length scales, which 462 
results in short observation time (Fule et al., 2016). In current studies, the molecular interaction 463 
between the EFV and xylitol and pearlitol respectively has been quantified by AFM. Cross 464 
sectional view and 3D surface morphology of SCS shows molecular level of interactions 465 
between drug and polymer (Lauer et al., 2013). AFM probes were employed to characterize 466 
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and map the distribution of components within a SCSs prepared by HME. The distribution of 467 
drug inside polymer shows homogenous morphology (Pawar et al., 2016a). The two phases 468 
were mixed at molecular level as reflected by normal AFM image (nanoscale) and 3D image 469 
processed via AFM. These studies were performed on the stability samples (6 month old) which 470 
consequently confirms the stability of prepared SCS formulations. 471 
3.11 Stability evaluation 472 
Drug content of developed SCS extrudates was determined using HPLC analysis. EFV 473 
analytical method validation was carried out according earlier reported literature (Pawar et al., 474 
2016b) Each batch of SCS were found in acceptable range as per US Pharmacopoeia for EFV. 475 
In addition, drug content analysis was also carried out for samples of 6 and 12-month 476 
accelerated storage conditions Fig. 14. It was found that drug content of SCS formulations 477 
made with pearlitol was in range of 96.03 to 101.60% with standard deviation values from 478 
0.966 to 1.68, respectively for fresh and 12 months accelerated storage conditions samples. 479 
However, SCS made using xylitol as a crystalline carrier showed decrease in drug content from 480 
100% to 87% and 99% to 91% in SCS1 and SCS2, respectively. The underlying reason may 481 
be thexylitol undergoing a caramelization reaction, and the tendency to form cakes upon 482 
storage to accelerated conditions (Repka et al., 2008; Rowe et al., 2009). Hence, SCS 483 
formulations made using xylitol failed in stability study. A further in detail study is needed to 484 
carry out to understand the instability issue. The results of the SCS formulations made using 485 
pearlitol as a carrier exibitshigh physical stability as well as chemical stability, confirmed from 486 
content uniformity values.  487 
4. Conclusions 488 
HME has successfully been exploited to manufacture EVF based SCS as an eﬀective 489 
technique to increase the dissolution rate of poorly water soluble drug. In this emerging 490 
approach crystalline drug substance is keept in its crystalline state. The use of mannitol and 491 
xylitol as crystalline carriers showed a faster drug release compared to that of the bulk drug . 492 
The optimized SCS1 formulation system showed 19-81 fold improvement in the solubiltiy  two 493 
different dissolution media and likewise the dissolution rates. The DSC and XRD analysis 494 
confirms that drug is present in stabilized crystalline form in the developed SCS formulation. 495 
FTIR analysis showed no chemical interaction between the API and sugar alcohols 496 
respectively. FTIR chemical imaging analysis has also confirmed the homogenous dispersions 497 
of the drug molecule into the sugar matrices. It can be concluded that the“solid crystal 498 
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suspension” approach by means of HME can be adopted as an alternative emerging technique  499 
particularly suitable for those drugs that are diﬃcult to stabilize in amorphous form. 500 
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